SNN Quote, Financials, Valuation and Earnings

Bicycle Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -1898.43%. Smith & Nephew PLC's return on equity of 5.85% beat Bicycle Therapeutics PLC's return on equity of -29.19%.

Smith & Nephew PLC has a consensus price target of $35.35, signalling upside risk potential of 32.66%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.36 which suggests that it could grow by 127.12%. Given that Bicycle Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Smith & Nephew PLC.

Smith & Nephew PLC has a beta of 0.845, which suggesting that the stock is 15.545% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.196%.

Smith & Nephew PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 3.06%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

Smith & Nephew PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $2.7M. Smith & Nephew PLC's net income of -- is lower than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 35.16x while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.90x versus 20.51x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 5.85% beat Biodexa Pharmaceuticals PLC's return on equity of --.

Smith & Nephew PLC has a consensus price target of $35.35, signalling upside risk potential of 32.66%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Smith & Nephew PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Smith & Nephew PLC.

Smith & Nephew PLC has a beta of 0.845, which suggesting that the stock is 15.545% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

Smith & Nephew PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 3.06%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Smith & Nephew PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Smith & Nephew PLC's price-to-earnings ratio is 35.16x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.90x versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Haleon PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of 17.45%. Smith & Nephew PLC's return on equity of 5.85% beat Haleon PLC's return on equity of 5.94%.

Smith & Nephew PLC has a consensus price target of $35.35, signalling upside risk potential of 32.66%. On the other hand Haleon PLC has an analysts' consensus of -- which suggests that it could grow by 10.65%. Given that Smith & Nephew PLC has higher upside potential than Haleon PLC, analysts believe Smith & Nephew PLC is more attractive than Haleon PLC.

Smith & Nephew PLC has a beta of 0.845, which suggesting that the stock is 15.545% less volatile than S&P 500. In comparison Haleon PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Smith & Nephew PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 3.06%. Haleon PLC offers a yield of 1.62% to investors and pays a quarterly dividend of $0.05 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Haleon PLC pays out 36.99% of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Smith & Nephew PLC's is not.

Smith & Nephew PLC quarterly revenues are --, which are smaller than Haleon PLC quarterly revenues of $3.6B. Smith & Nephew PLC's net income of -- is lower than Haleon PLC's net income of $631.1M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 35.16x while Haleon PLC's PE ratio is 28.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.90x versus 3.13x for Haleon PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -763.91%. Smith & Nephew PLC's return on equity of 5.85% beat Verona Pharma PLC's return on equity of -74.15%.

Smith & Nephew PLC has a consensus price target of $35.35, signalling upside risk potential of 32.66%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 4.43%. Given that Smith & Nephew PLC has higher upside potential than Verona Pharma PLC, analysts believe Smith & Nephew PLC is more attractive than Verona Pharma PLC.

Smith & Nephew PLC has a beta of 0.845, which suggesting that the stock is 15.545% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.579%.

Smith & Nephew PLC has a quarterly dividend of $0.29 per share corresponding to a yield of 3.06%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Smith & Nephew PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. Smith & Nephew PLC's net income of -- is lower than Verona Pharma PLC's net income of -$43M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 35.16x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.90x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.